Glucagon and insulin are commonly believed to have counteracting effects on blood glucose levels. However, recent studies have demonstrated that glucagon has a physiologic role to activate β cells and enhance insulin secretion. To date, the actions of glucagon have been studied mostly in fasting or hypoglycemic states, yet it is clear that mixed-nutrient meals elicit secretion of both glucagon and insulin, suggesting that glucagon also contributes to glucose regulation in the postprandial state. We hypothesized that the elevated glycemia seen in the fed state would allow glucagon to stimulate insulin secretion and reduce blood glucose. In fact, exogenous glucagon given under fed conditions did robustly stimulate insulin secretion and lower glycemia. Exogenous glucagon given to fed Gcgr:Glp1rβcell–/– mice failed to stimulate insulin secretion or reduce glycemia, demonstrating the importance of an insulinotropic glucagon effect. The action of endogenous glucagon to reduce glycemia in the fed state was tested with administration of alanine, a potent glucagon secretagogue. Alanine raised blood glucose in fasted WT mice or fed Gcgr:Glp1rβcell–/– mice, conditions where glucagon is unable to stimulate β cell activity. However, alanine given to fed WT mice produced a decrease in glycemia, along with elevated insulin and glucagon levels. Overall, our data support a model in which glucagon serves as an insulinotropic hormone in the fed state and complements rather than opposes insulin action to maintain euglycemia.
Megan E. Capozzi, Jacob B. Wait, Jepchumba Koech, Andrew N. Gordon, Reilly W. Coch, Berit Svendsen, Brian Finan, David A. D’Alessio, Jonathan E. Campbell
Title and authors | Publication | Year |
---|---|---|
Islet protein expression of GLP-1 receptor, but not GLP-1, is reduced in cystic fibrosis-related diabetes
Sina Gharib, Rachna Vemireddy, Joseph Castillo, Brendy Fountaine, Theo Bammler, James MacDonald, Rebecca Hull, Sakeneh Zraika |
Scientific reports | 2024 |
Paracrine signalling by pancreatic δ cells determines the glycaemic set point in mice.
Huang JL, Pourhosseinzadeh MS, Lee S, Krämer N, Guillen JV, Cinque NH, Aniceto P, Momen AT, Koike S, Huising MO |
Nature metabolism | 2024 |
High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans.
Gray SM, Goonatilleke E, Emrick MA, Becker JO, Hoofnagle AN, Stefanovski D, He W, Zhang G, Tong J, Campbell J, D'Alessio DA |
Diabetes | 2024 |
Differential effects of fish-oil and cocoa-butter based high-fat/high-sucrose diets on endocrine pancreas morphology and function in mice
Albeloushi S, Hasan A, Arefanian H, Sindhu S, Al-Rashed F, Kochumon S, Abukhalaf N, Jacob T, Shenouda S, Al Madhoun A, Al-Mulla F, Ahmad R |
Frontiers in Endocrinology | 2024 |
The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic β-Cell Function and Diabetes.
Varney MJ, Benovic JL |
Pharmacological reviews | 2024 |
Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes
D\u2019Souza NC, Aiken JA, Hoffman EG, Atherley SC, Champsi S, Aleali N, Shakeri D, El-Zahed M, Akbarian N, Nejad-Mansouri M, Bavani PZ, Liggins RL, Chan O, Riddell MC |
Frontiers in pharmacology | 2024 |
The Importance of Intra-Islet Communication in the Function and Plasticity of the Islets of Langerhans during Health and Diabetes
Hill TG, Hill DJ |
International journal of molecular sciences | 2024 |
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
Chrysavgis LG, Kazanas S, Bafa K, Rozani S, Koloutsou ME, Cholongitas E |
International journal of molecular sciences | 2024 |
From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity
Kistkins S, Moser O, Ankudovičs V, Blizņuks D, Mihailovs T, Lobanovs S, Sourij H, Pfeiffer AF, Pīrāgs V |
Endocrine Connections | 2024 |
Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence
McGlone ER, Bloom SR, Tan TM |
The Journal of endocrinology | 2024 |
Urocortin3 contributes to paracrine inhibition of islet alpha cells in mice
Noguchi GM, Castillo VC, Donaldson CJ, Flisher MR, Momen AT, Saghatelian A, Huising MO |
The Journal of endocrinology | 2024 |
Lipid regulation of the glucagon receptor family
Oqua AI, Manchanda Y, McGlone ER, Jones B, Rouse S, Tomas A |
The Journal of endocrinology | 2024 |
Sex-dependent intra-islet structural rearrangements affecting alpha-to-beta cell interactions lead to adaptive enhancements of Ca(2+) dynamics in prediabetic beta cells.
Visa M, Berggren PO |
Diabetologia | 2024 |
Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes.
Moon JH, Choe HJ, Lim S |
Journal of Diabetes Investigation | 2024 |
Intra-islet α-cell Gs signaling promotes glucagon release
Liu L, Kimberley EI, Dattaroy D, Barella LF, Cui Y, Guedikian C, Chen M, Weinstein LS, Knuth E, Jin E, Merrins MJ, Roman J, Kaestner KH, Doliba N, Campbell JE, Wess J |
Nature Communications | 2024 |
Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homoeostasis
Suba K, Patel Y, Martin-Alonso A, Hansen B, Xu X, Roberts A, Norton M, Chung P, Shrewsbury J, Kwok R, Kalogianni V, Chen S, Liu X, Kalyviotis K, Rutter GA, Jones B, Minnion J, Owen BM, Pantazis P, Distaso W, Drucker DJ, Tan TM, Bloom SR, Murphy KG, Salem V |
Molecular Metabolism | 2024 |
Regulatory Role of Fatty Acid Metabolism on Glucose-Induced Changes in Insulin and Glucagon Secretion by Pancreatic Islet Cells
Tamarit-Rodriguez J |
International journal of molecular sciences | 2024 |
Dietary protein, amino acids and type 2 diabetes mellitus: a short review
Mensink M |
Frontiers in Nutrition | 2024 |
V1bR enhances glucose-stimulated insulin secretion by paracrine production of glucagon which activates GLP-1 receptor
Yun Y, Guo S, Xie X |
Cell & Bioscience | 2024 |
Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet.
Lewandowski SL, El K, Campbell JE |
American journal of physiology. Endocrinology and metabolism | 2024 |
Phosphoproteomics-directed manipulation reveals SEC22B as a hepatocellular signaling node governing metabolic actions of glucagon
Wu Y, Foollee A, Chan AY, Hille S, Hauke J, Challis MP, Johnson JL, Yaron TM, Mynard V, Aung OH, Cleofe MA, Huang C, Lim Kam Sian TC, Rahbari M, Gallage S, Heikenwalder M, Cantley LC, Schittenhelm RB, Formosa LE, Smith GC, Okun JG, Müller OJ, Rusu PM, Rose AJ |
Nature Communications | 2024 |
Engineered tools to study endocrine dysfunction of pancreas
Alver CG, Dominguez-Bendala J, Agarwal A |
Biophysics Reviews | 2024 |
Alterations in Glucagon Levels and the Glucagon-to-Insulin Ratio in Response to High Dietary Fat or Protein Intake in Healthy Lean Adult Twins: A Post Hoc Analysis
Schuppelius B, Schüler R, Pivovarova-Ramich O, Hornemann S, Busjahn A, Machann J, Kruse M, Park SQ, Kabisch S, Csanalosi M, Ost AC, Pfeiffer AF |
Nutrients | 2024 |
Characterization of LY3324954 a long-acting glucagon-receptor agonist
Roell W, Coskun T, Kim T, O\u2019Farrell L, Martin JA, Nason S, Hernandez-Alamillo J, Dhantu S, Drucker DJ, Sloop KW, Steele JP, Alsina-Fernandez J, Habegger KM |
Molecular Metabolism | 2024 |